In addition, by treating samples (PBMC) from STAT3-mutated T-LGLL patients with Stattic, a STAT3 inhibitor, we observed a significant reduction of PVT1 RNA (Fig. 3C), consistent with the lower PVT1 expression observed in T-LGLL cases with STAT3 wild-type. This evidence concerns the gene PVT1 and T-cell large granular lymphocyte leukemia.